Quote

"The bottom line ... is that most of these drugs [in the Alzheimer's pipeline], given the size, length and cost of these phase III trials, are likely not to reach the market for another four to five years. At that time, the impact within this class of drugs for most payers is likely to be quite significant, as these newer developments will shift treatment away from a moderately priced small molecule drug market, to a far more expensive array of biologic therapies with potential to become the new future standard of care in a growing Alzheimer's patient population."


— David Calabrese, R.Ph, vice president and chief pharmacy officer for Catamaran Corp., told AIS's Drug Benefit News.